title: Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK.
abstract: Neisseria meningitidis is the main cause of bacterial meningitis and sepsis in the UK, and can potentially be lethal or cause long-term sequelae. Bexsero® (4CMenB) is a new multi-component vaccine approved by the European Commission for use in individuals aged ⩾2 months. A theoretical transmission model was constructed to assess the long-term effectiveness of Bexsero compared to standard care. The model was populated with UK-specific demographic data and calibrated to ensure that the transmission dynamics of meningococcal disease in the UK were adequately simulated. The model showed the best strategy to be a routine vaccination programme at ages 2, 3, 4, 12 months and 14 years combined with a 5-year catch-up programme in toddlers aged 12-24 months and adolescents aged 15-18 years. This would lead to a 94% reduction in meningococcal cases or 150 000 cases and 15 000 deaths over a 100-year time-frame.
authors.affiliation: Novartis Vaccines and Diagnostics Limited,Basel,Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Huels
authors.affiliation: OptumInsight, Cambridge, MA,USA.
authors.forename: K M
authors.initials: KM
authors.lastname: Clements
authors.affiliation: OptumInsight, Cambridge, MA,USA.
authors.forename: L J
authors.initials: LJ
authors.lastname: McGARRY
authors.affiliation: OptumInsight, Cambridge, MA,USA.
authors.forename: G J
authors.initials: GJ
authors.lastname: Hill
authors.affiliation: Novartis Vaccines and Diagnostics Inc.,Cambridge, MA,USA.
authors.forename: J
authors.initials: J
authors.lastname: Wassil
authors.affiliation: Novartis Vaccines and Diagnostics Limited,Basel,Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Kessabi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D008589:Meningococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology*; D008875:Middle Aged; D008954:Models, Biological; D009345:Neisseria meningitidis / Q000145:classification / Q000276:immunology; D035501:Uncertainty; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult
chemical_list: C570015:4CMenB vaccine; D022401:Meningococcal Vaccines